• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Application and prospect of adipose stem cell transplantation in treating lymphedema

    2020-08-10 01:51:48ZhuJunLiElanYangYunZhuLiZhengYunLiangJiuZuoHuangNanZeYuXiaoLong
    World Journal of Stem Cells 2020年7期

    Zhu-Jun Li, Elan Yang, Yun-Zhu Li, Zheng-Yun Liang, Jiu-Zuo Huang, Nan-Ze Yu, Xiao Long

    Zhu-Jun Li, Elan Yang, Yun-Zhu Li, Zheng-Yun Liang, Jiu-Zuo Huang, Nan-Ze Yu, Xiao Long, Department of Plastic and Reconstructive Surgery, Peking Union Medical College Hospital of Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100730, China

    Abstract

    Key words: Lymphedema; Adipose-derived stem cells; Animal model; Clinical trial; Vascular endothelial growth factor-C; Lymphangiogenesis

    INTRODUCTION

    As the second circulatory system of the body, the lymphatic system functions to transport tissue fluid in the interstitial space back to the venous circulation system and maintain fluid homeostasis.Hypoplasia or dysfunction of lymphatic vasculature may result in “l(fā)ymphedema”[1], which is characterized by retention of lymphatic fluid in the interstitial space, leading to a series of pathological changes, including tissue swelling, chronic inflammation, lipid deposition, and tissue fibrosis[2].

    There are two types of lymphedema according to etiology[3].Primary lymphedema comes from developmental or congenital abnormalities of the lymphatic system resulting in dysfunctional lymphatics, which could be symptomatic at birth or more commonly in adolescence.Secondary lymphedema is more common and results from trauma, obstruction, surgery, or infection involving the lymphatic system.Up to 250 million people in developing countries suffer from lymphedema, with the parasitic disease filariasis as the most prevalent cause[4]; lymphadenectomy and radiation therapy for cancer treatment are usually the major causes of lymphedema in developed countries.

    Chronic lymphedema affects 0.13%-2% of the global population[5].It is estimated that one out of six patients undergoing treatment for a solid tumor will eventually develop lymphedema[6].For patients with breast cancer, 24%-49% of those receiving mastectomy will develop upper extremity lymphedema[7].The persistence of the disease, burden of treatment, and likelihood of progression press heavy medical and socioeconomic burdens onto patients.Therefore, development of effective therapies for lymphedema is of vital importance.

    Lymphedema can be treated conservatively, surgically, or by a combination of them[2].Conservative therapies consist of complex decongestive therapy, manual lymphatic drainage, and exercise[8].Surgical therapies include liposuction, wedge resection, Charles procedure (radical excision for limb lymphedema), and lymphatic reconstruction or bypass techniques[9].However, there is a lack of effective and feasible therapies which could radically cure lymphedema[10].Therefore, elucidating the underlying pathophysiological mechanisms of lymphedema holds promise for the treatment of lymphedema.

    Progenitor or stem cell-based therapies, which treat diseases through regeneration, have represented an alternative treatment method not only for lymphedema but for a wide spectrum of other diseases as well.Due to their abundant resources, easy access, pluripotent capacity, and harboring of few ethical and immunological issues, the adipose-derived stem cells (ADSCs) are considered as one of the most promising seed cell types for regenerative medicine[11-15].In addition, ADSCs exhibit paracrine immunomodulatory and trophic effects in their local microenvironment.Emergingin vitrostudies have investigated the possible mechanisms and benefit of ADSCs in the treatment of lymphedema, such as their capacity for differentiation into lymphatic endothelial cells (LECs)[16,17]and paracrine secretion of cytokines[18], chemokines[19]and exosomes[20], thereby promoting angiogenesis and modulating the immune response.Takedaet al[21]reported that, by secreting lymphangiogenic factors, ADSCs promote proliferation, migration, and tube formation of LECsin vitro.Denget al[22]demonstrated that overexpression of Prox1 in human ADSCs (vialentiviral vectors) induces the differentiation of human ADSCs into stable lymphatic endothelial-like cellsin vitroand that the differentiated cells form tube-like structures (as shown in tube formation assay).Yenet al[23]showed that ADSCs promote lymphangiogenesis under stimulation of vascular endothelial growth factor-C (VEGF-C), a key lymphangiogenic factor, or in response to inhibition of TGF-β1; moreover, stimulation of ADSCs with VEGF-C was found to markedly increase cellular proliferation and cellular survival afterin vivoimplantation and to induce the expression of podoplanin, a lymphangiogenic cell marker.Sunet al[19]reported that interleukin-7 enhanced the differentiation of ADSCs into LECsviaAKT signaling pathways.Most recently, Saijoet al[24]revealed that paracrine effects of ADSCs promoted lymphangiogenesis in irradiated LECs.They reported that coculture with ADSCs and the use of ADSCconditioned medium improved proliferation, migration, and tube formation of nonirradiated LECs.Furthermore, they demonstrated that irradiated ADSCs can exert similar alleviative effects to irradiated human dermal LECs[24].

    Collectively, these research findings have suggested that ADSCs might serve as suitable seed cells for lymphatic tissue engineering and secondary lymphedema therapy.The aim of this review is to systematically summarize the application of ADSCs for lymphedema treatment in animal studies and in clinical trials.In addition, the future perspectives of ADSCs in lymphedema therapy are discussed.

    MATERIALS AND METHODS

    A systematic search was performed on four databases (PubMed, Clinicaltrials.gov, the evidence-based Cochrane library, and OVID) using the following search string: (“l(fā)ymphedema” or “l(fā)ymphoedema” or “l(fā)ymphangiogenesis”) and (“adipose-derived stem cells” or “adipose-derived stromal cells” or “adipose-derived regenerative cells”).After duplicate removal, all studies were screened based on title and abstract.Furthermore, full-text versions of included studies were read for further evaluation.A manual search was also performed by skimming the references of included studies.The search process is presented in Figure 1.

    The inclusion criteria were animal studies and clinical trials using adipose-derived cells for treatment of any kind of lymphedema, which had been published no later than November 2019.The exclusion criteria were non-English language, reviews, orin vitrostudies.For animal studies, data retrieved were year of publication, first author, type of animal models, cell type used (freshly isolated or culture-expanded as well as autologous or allogeneic), cell dosage, cell characterization (cell count/viability, surface marker analysis,etc.), means and routes of transplantation (alone or in combination with growth factors, scaffolds,etc.), assessment types, and results.For clinical trials, data retrieved were year of publication, country of origin, disease treated, study design (randomized controlled trial, nonrandomized study, or case series/pilot study), number of participants, cell type used (freshly isolated or cultureexpanded as well as autologous or allogeneic), cell dosage, cell characterization (cell count/viability, surface marker analysis,etc.), means and routes of transplantation (alone or in combination with growth factors, scaffolds,etc.), assessment types, and outcomes.

    Figure 1 Search process of articles regarding adipose-derived stem cell-based treatment of lymphedema studied in animal models and clinical trials.

    RESULTS

    A total of eight research articles published before November 2019 met the inclusion criteria for this analysis.These included five articles focused on animal studies (Table 1) and three focused on clinical trials (Table 2).

    Animal studies

    A total of five animal studies were included in the analysis.Commonly-used animal models were mouse hindlimb or tail model of lymphedema.The surgical procedures were circumferential incision with or without radiation.The number of cells used for injection varied from 104to 1010each time.Various treatments were used in combination with cell injection, including controlled-release VEGF-C, platelet-rich plasma (PRP), or vascularized lymph node transfer.Treatment outcomes were evaluated by circumference, dermal edema depth, imaging (lymphangiography and photodynamic dye), and histochemical and immunohistochemical staining (for CD31, LYVE1, and VEGF receptor).

    Hwanget al[25]established a mouse hindlimb model of lymphedema by electrocauterizing the lymph vessels in the thigh following a circumferential incision.In vivostudy demonstrated that combination of human (h) ADSCs and VEGF-C hydrogel markedly alleviated dermal edema and increased lymphatic vessel density when compared with results achieved with hADSCs or VEGF-C hydrogel alone at various post-treatment time points (from 3-4 d to 4 wk post-treatment).In addition, the authors demonstrated the existence of hADSCs in all of the implantation sites in the hADSC/VEGF-C group with LECs phenotype.Their results also suggested that, in conjunction with hADSCs, VEGF-C-containing hydrogels could serve as suitable delivery vectors to improve lymphangiogenesis.

    Shimizuet al[26]reported on the establishment of a mouse tail model of lymphedema.They made a 2 mm-wide circumferential excision on the skin 10 mm distal to the tail base and excluded a 4 mm2dermal flap at the ventral side.They indicated that local injection of 2 × 106freshly isolated autologous ADSCs could reduce lymphedema and accelerate lymphangiogenesis at the congestive lymphedema region.The authors also revealed that ADSCs could release VEGF-C to stimulate lymphangiogenesis and recruit bone marrow-derived M2 macrophages to serve as lymphatic endothelial progenitor cells.

    Ackermannet al[27]assessed the effects of PRP and adipose stem cells on angiogenesis, microcirculation, lymphangiogenesis, microvascular architecture, and wound healing in a mouse tail lymphedema model.They found that treatment with PRP and adipose stem cells could accelerate wound healing and increase epithelialization.PRP application induced a remarkably improved lymphangiogenesis.Ultimately, the authors drew the conclusion that PRP and adipose stem cells can affect lymphangiogenesis and lymphedema development.

    Table 1 Adipose-derived stem cell-based treatment of lymphedema in animal studies

    ADRCs: Adipose-derived regenerative cells; ADSCs: Adipose-derived stem cells; ASC: Adipose stem cells; EGFP: Enhanced green fluorescent protein; FISH: Fluorescent in situ hybridization; H&E: Hematoxylin and eosin; hADSCs: Human adipose-derived stem cells; IFC: Immunofluorescence; IHC: Immunohistochemistry; N/A: Not applicable; PBS: Phosphate-buffered saline; VEGF-C: Vascular endothelial growth factor-C; VEGF-R3: Vascular endothelial growth factorreceptor 3; VLNT: Vascularized lymph node transfer.

    Yoshida et al[28]reported on the establishment of a mouse right hindlimb secondary lymphedema model, using 30 Gy X-ray irradiation 7 d before surgery to create a circumferential incision and a gap of approximately 2 mm, left open.Circumferential measurement, lymphatic flow assessment, and quantification of lymphatic vessels demonstrated that at 14 d post-treatment of local injection with 106ADSCs, 105ADSCs, or 104ADSCs, the numbers of lymphatic vessels were significantly increased in the transplanted groups; the authors concluded that in secondary lymphedema, ADSCs could increase collecting vessels and reconstruct the lymphatic vascular network.A more recent study from the same research group[29]demonstrated that local implantation of 104ADSCs in combination with vascularized lymph node transfer decreased tissue volume, increased lymphatic vessels density, and improved the lymphatic function in a slightly different mouse hindlimb model (left vs right hindlimb, 5 mm- vs 2 mm-wide gap, left open).

    Clinical trials

    A total of three clinical trials were included in the analysis.All these studies were conducted by the same research group in Denmark[25-27], focusing on upper limb and breast cancer-related lymphedema (BCRL), using freshly isolated autologous ADSCs with fat grafting.The follow-up period ranged from 4 mo to 1 year.

    Table 2 Adipose-derived stem cell treatment of lymphedema in clinical trials

    In 2016, Toyserkaniet al[30]reported a pilot study using ADSC-assisted lipotransfer to treat lymphedema.A 48-year-old female patient developed BCRL after lymphadenectomy and radiation therapy.A total of 4.07 × 107freshly isolated autologous ADSCs were administered, along with 10 mL of lipoaspirate (for fatgrafting), to the axillary region.At 4 mo post-treatment, the authors noted that the daily symptoms of arm heaviness and tension were greatly relieved, the needs for compression therapy were reduced, and the volume of the affected arm was decreased without postoperative complications or adverse events.

    Furthermore, the authors had also performed a larger study to validate the feasibility and safety of this procedure in 2007[31], which was registered at Clinicaltrials.gov under the identifier NCT02592213 at phase 2 stage.In this pilot study, ten BCRL patients were included.Combined with a scar-releasing fat graft (about 30 mL) procedure, approximately 5 × 107freshly isolated adipose-derived regenerative cells (ADRCs) were injected into the axillary region.During a 6-mo follow-up period, there was a small but not significant volume reduction.Five of the patients showed a reduced need for conservative treatment, and patient-reported follows-up improved significantly over time.Slight, temporary adverse events were observed, but were more likely caused by liposuction procedures rather than ADRC injection.Ultimately, the ADRCs were deemed as well-tolerated.

    In 2019, the results of lymphoscintigraphic evaluation with 1-year follow-up were reported[32].Consistent with the results of the 6-mo follow-up, ADRC injection improved lymphedema, as revealed by patient-reported outcomes without serious adverse events.However, there was no improvement in lymphoscintigraphic evaluation and no change in arm volume after the ADRC treatment.Now, this research group is recruiting patients for a randomized phase 3 trial, which is registered at Clinicaltrials.gov under the identifier NCT03776721.This study started December 17, 2018 and the estimated study completion date is September 1, 2021, designed to recruit 80 participants with a parallel assignment to evaluate the efficacy and safety of implantation of freshly isolated adipose-derived stromal cells in combination with fat grafting at the affected axillary region.

    DISCUSSION

    Lymphedema, characterized by tissue swelling, lipid deposition, and fibrosis due to excess accumulation of interstitial fluid and inadequate lymphatic drainage, affects 0.13%-2% of the global population[5]and remains a chronic, debilitating and incurable disease.Stem cell-based regenerative medicine has shown great promise for refractory diseases, such as inflammatory bowel diseases[33], heart failure[34], osteoarthritis[35], rheumatoid arthritis[36], and graft-versus-host disease[37].With the properties of selfrenewal, multipotential differentiation, paracrine, immunomodulatory, and trophic effects, and low immunogenicity alongside their practical advantages, ADSCs have become one of the most promising candidates for regenerative medicine.

    ADSCs are isolated from the aqueous fraction – known as the stromal vascular fraction (SVF) – by means of enzymatic digestion of lipoaspirate (liposuction product)[38,39].As the major source of ADSCs, SVF is a heterogeneous cell group composed of ADSCs, endothelial precursor cells, endothelial cells, macrophages, smooth muscle cells, lymphocytes, pericytes, and pre-adipocytes derived from fat tissue.Recent advances have shown the role and efficacy of SVF and ADSCs in improvement of tissue regeneration, especially in plastic reconstruction[40], such as breast reconstruction[41,42], wound healing[43,44], scars[45,46], and soft tissue defects[47].The SVF is more easily obtained, regardless of cell separation and culture conditions.Therefore, therapeutic cellular products are obtained immediately with minimal contact with reagents, making it not only technically easier but also relatively safer.At the same time, the unique heterogeneous cell components of SVF may achieve better treatment results in comparative animal studies.It is worth noting that SVF might be suitable for autologous therapy only, due to the existence of various cell types that might cause immunological rejection[48], whereas ADSCs are useful in both allogenic therapy and autologous therapy.

    As mentioned in the first part of this review, emergingin vitrostudies have already definitively demonstrated the advantage of ADSCs in lymphangiogenesis and treatment of lymphedema.All five animal studies included in this systematic review were performed on mouse models and the ADSCs were injected immediately or shortly after lymphedema induction.These studies examined the effect of ADSCs on acute lymphedema and exhibited improvement at 4-6 wk.However, the anatomy, physiology, and healing capacity are quite different between mice and human beings, bringing up the need for larger animal models in order to simulate chronic lymphedema in human beings more accurately.Further preclinical studies with better animal models are needed to determine whether ADSC-based therapies could fulfil expectations and be extrapolated to clinical use in patients.As is commonly known, to observe lymphatics in mice, it is usually necessary to visualize the blue dye-stained lymphatic vessels in dissected tissues or tissue sectioning for immunohistological staining for the lymphatic markers, such as VEGFR-3, PROX1, and LYVE1, to quantitatively identify lymphatic vessel intensity and lymphangiogenesis.Advances in near-infrared fluoroscopy lymphatic imaging[49], magnetic resonance imaging agents based on nanotechnology, and gene reporter technologies have paved roads for depicting functions of lymphatic vasculature.Though not all lymphatic imaging methods are suitable for both clinical and preclinical trials, their effective combination will provide new tools for lymphedema translational medicine[50].

    Therapy of lymphedema has benefitted substantially from the most recent advances in lymphatic vessel engineering and regenerative medicine, including cell-seeded scaffolds for vessel reconstruction, implantation of stem cells, prolymphangiogenic growth factors, or a combination of these technologies.As mentioned above, when implanted into the injury site in a lymphedema mouse model, the gelatin hydrogel containing controlled-release VEGF-C could encapsulate hADSCs, increase vessel density, and improve dermal edema, leading to efficient application in lymphatic vessel regeneration[25].It has been reported that SVFs and ADSCs could improve wound healing when used alone or in combination with PRP and hyaluronic acid, specifically in healing of lower-extremity soft- and hard-tissue wounds[43]and in severe hidradenitis suppurativa wounds[47].Many other studies confirmed that SVFs and ADSCs can improve wound healing when used alone or in combination with PRP and fat graft[41,45,51,52].Considering the similar biological processes and biomolecular pathways shared between wound healing and lymphedema, such as inflammation and angiogenesis, the efforts towards establishing ADSCs-based therapy for lymphedema will benefit from these studies.Certainly, the research efforts towards development of cell isolation and expansion methods and of three-dimensional scaffolds[53], nanoparticles, and targeted delivery will help to optimize and maximize the efficacy of ADSC-assisted therapy.Standardized platforms with minimized manipulations and maximized efficacy will facilitate both up-scaling and the ease of clinical translation.

    Over the past few years, concerns regarding the safety of stem cell application have also been raised.Indeed, Toyserkaniet al[54]performed a systematic review, including over 1400 patients who received ADSC treatment and were followed for 4 wk to 3 years, in order to assess the safety of ADSC therapy, concentrating on the risks of thromboembolical, immunological, and oncological safety concerns.They reported that the observed adverse outcomes were relevant to liposuction, injuries from implantation, or the underlying condition, rather than the ADSC therapy itself.Although the ADSC therapy has shown a favorable safety performance, more reliable and rigorous safety assessment approaches are still encouraged for further study and clinical practice.

    In conclusion, the results ofin vitrostudies, animal models, and clinical trials characterize ADSC-based treatment as a promising option and one that can be used within biologically rational and controllable environments for the treatment of lymphedema.However, further investigations in larger animal models and largerscale, multicenter randomized clinical trials with more reliable and rigorous safety assessments are needed to develop more effective and durable therapeutic strategies.

    ARTICLE HIGHLIGHTS

    Research background

    Lymphedema is a chronic, debilitating and incurable disease that affects 0.13%-2% of the global population.Emerging evidence indicates that adipose-derived stem cells(ADSCs) might serve as suitable seed cells for lymphatic tissue engineering and lymphedema therapy.Here, we appraise the in vivo evidence for the application of ADSCs for lymphedema treatments.

    Research motivation

    Emerging research findings have suggested that ADSCs might serve as suitable seed cells for tissue engineering of lymphatic vessels in vitro and potentially in the treatment of secondary lymphedema in vivo.It is critical that we systematically summarize the application of ADSCs for lymphedema treatments in animal studies and in clinical trials and discuss the future perspectives.

    Research objectives

    The main objectives of this review are to systematically summarize the application of ADSCs for lymphedema treatments as shown in animal studies and clinical trials.In addition, the future perspectives of ADSCs in lymphedema therapy are discussed.

    Research methods

    A systematic search was performed on four databases – PubMed, Clinicaltrials.gov, the evidence-based Cochrane library, and OVID – using the following search string: (“l(fā)ymphedema” or “l(fā)ymphoedema” or “l(fā)ymphangiogenesis”) and (“adipose-derived stem cells” or “adipose-derived stromal cells” or “adipose-derived regenerative cells”).A manual search was performed by skimming the references of relevant studies.Animal studies and clinical trials using adipose-derived cells for the treatment of any kind of lymphedema were included.

    Research results

    A total of eight research articles published before November 2019 were included for this analysis.Five articles focused on animal studies and another three focused on clinical trials.ADSC transplantation therapy was demonstrated to be effective against lymphedema in all studies.The animal studies found that coadministration of ADSCs and controlled-release vascular endothelial growth factor-C or platelet-rich plasma could improve the effectiveness of ADSC therapy.Three sequential clinical trials were conducted on breast cancer-related lymphedema patients, and all showed favorable results.

    Research conclusions

    The results ofin vitrostudies, animal models, and clinical trials characterize ADSCbased treatment as a promising option and one that can be used within biologically rational and controllable environments for the treatment of lymphedema.

    Research perspectives

    Further preclinical studies in larger animal models and large-scale, multicenter randomized controlled clinical trials with more reliable and rigorous safety assessments are needed to develop more effective and durable therapeutic strategies.Advances in lymphatic imaging methods will provide opportunities for lymphedema translational medicine as well.

    久久亚洲精品不卡| 午夜亚洲福利在线播放| 精品熟女少妇八av免费久了| 正在播放国产对白刺激| 99精品在免费线老司机午夜| 麻豆成人av在线观看| 国产精品影院久久| 国产91精品成人一区二区三区| 中文字幕人妻丝袜制服| 国产区一区二久久| 亚洲一区二区三区不卡视频| 91成人精品电影| 国产一区二区在线av高清观看| 亚洲人成电影观看| 亚洲男人的天堂狠狠| 国产亚洲精品综合一区在线观看 | 久久久精品欧美日韩精品| 欧美精品一区二区免费开放| 中出人妻视频一区二区| 日韩国内少妇激情av| 97碰自拍视频| 天堂√8在线中文| 丝袜人妻中文字幕| 亚洲欧洲精品一区二区精品久久久| 老司机深夜福利视频在线观看| 成人国产一区最新在线观看| 国产精品爽爽va在线观看网站 | 黄片小视频在线播放| 久久久久久久精品吃奶| 一级片'在线观看视频| 午夜福利影视在线免费观看| 亚洲国产精品999在线| 亚洲av成人av| 久久午夜亚洲精品久久| xxxhd国产人妻xxx| 热re99久久国产66热| 妹子高潮喷水视频| 一二三四社区在线视频社区8| 1024视频免费在线观看| 久久午夜综合久久蜜桃| 欧美日韩黄片免| 在线永久观看黄色视频| 99riav亚洲国产免费| 法律面前人人平等表现在哪些方面| 欧美人与性动交α欧美软件| 波多野结衣av一区二区av| 国产免费现黄频在线看| 日本vs欧美在线观看视频| 日日爽夜夜爽网站| 久久久久久人人人人人| 国产精品日韩av在线免费观看 | 人人妻人人添人人爽欧美一区卜| 亚洲精品在线美女| 国产欧美日韩一区二区三| 一个人观看的视频www高清免费观看 | 日韩视频一区二区在线观看| 日韩一卡2卡3卡4卡2021年| 99精品在免费线老司机午夜| av天堂在线播放| 露出奶头的视频| 日本wwww免费看| 日日摸夜夜添夜夜添小说| 欧美亚洲日本最大视频资源| 久久精品人人爽人人爽视色| 日韩有码中文字幕| 午夜91福利影院| 97碰自拍视频| 国产精品爽爽va在线观看网站 | 国产三级黄色录像| 欧美人与性动交α欧美精品济南到| 91老司机精品| 欧美日韩黄片免| 亚洲激情在线av| 久久天躁狠狠躁夜夜2o2o| 欧洲精品卡2卡3卡4卡5卡区| 曰老女人黄片| 宅男免费午夜| 一级作爱视频免费观看| 丁香六月欧美| 日韩免费av在线播放| 19禁男女啪啪无遮挡网站| 麻豆国产av国片精品| 淫妇啪啪啪对白视频| 丰满饥渴人妻一区二区三| 精品乱码久久久久久99久播| 操出白浆在线播放| 女人爽到高潮嗷嗷叫在线视频| 国产av在哪里看| 久久久精品欧美日韩精品| e午夜精品久久久久久久| 成人永久免费在线观看视频| 久久国产精品男人的天堂亚洲| 性色av乱码一区二区三区2| 欧美黄色淫秽网站| 老司机亚洲免费影院| 欧美在线黄色| 在线观看午夜福利视频| 高潮久久久久久久久久久不卡| 夜夜看夜夜爽夜夜摸 | 精品久久久久久成人av| 一级a爱视频在线免费观看| 精品人妻在线不人妻| 久久久久久久久久久久大奶| 91老司机精品| 亚洲精品在线观看二区| cao死你这个sao货| 9色porny在线观看| 老司机靠b影院| 久久久水蜜桃国产精品网| 一级作爱视频免费观看| 热99国产精品久久久久久7| 99re在线观看精品视频| 色精品久久人妻99蜜桃| 精品国产乱子伦一区二区三区| 黄色 视频免费看| 日韩三级视频一区二区三区| 国产麻豆69| 国产亚洲精品一区二区www| 亚洲国产精品999在线| 久久久久久久精品吃奶| 日韩大尺度精品在线看网址 | 欧美日本中文国产一区发布| 国产区一区二久久| 一边摸一边做爽爽视频免费| 99国产精品免费福利视频| 久久九九热精品免费| xxxhd国产人妻xxx| 搡老岳熟女国产| 母亲3免费完整高清在线观看| 成人18禁在线播放| 欧美一区二区精品小视频在线| 色综合站精品国产| 亚洲成a人片在线一区二区| 欧美国产精品va在线观看不卡| 国产一区在线观看成人免费| 国产色视频综合| 精品国内亚洲2022精品成人| 亚洲欧美日韩无卡精品| 午夜精品在线福利| 欧美性长视频在线观看| 天堂动漫精品| 国产单亲对白刺激| 九色亚洲精品在线播放| 欧美日韩中文字幕国产精品一区二区三区 | 久久久久久久久久久久大奶| 一级毛片精品| 久久国产精品男人的天堂亚洲| 亚洲精华国产精华精| 久久热在线av| 久久久国产欧美日韩av| 国产一区二区激情短视频| 久久天躁狠狠躁夜夜2o2o| 老司机福利观看| av电影中文网址| av天堂在线播放| 99精品欧美一区二区三区四区| 国产成人精品在线电影| 国产精品久久视频播放| e午夜精品久久久久久久| 国产人伦9x9x在线观看| 午夜免费鲁丝| 一级黄色大片毛片| 黄色视频,在线免费观看| 人成视频在线观看免费观看| 亚洲欧美激情综合另类| 久久精品国产99精品国产亚洲性色 | 亚洲精品中文字幕一二三四区| 国产精品 欧美亚洲| 日本黄色视频三级网站网址| 精品国产乱码久久久久久男人| 国产激情久久老熟女| 黄网站色视频无遮挡免费观看| 亚洲精品国产精品久久久不卡| 国产亚洲欧美98| 亚洲专区国产一区二区| 一个人免费在线观看的高清视频| svipshipincom国产片| 热re99久久精品国产66热6| av有码第一页| 法律面前人人平等表现在哪些方面| 国产无遮挡羞羞视频在线观看| 90打野战视频偷拍视频| 级片在线观看| 国产亚洲精品第一综合不卡| 黄片大片在线免费观看| 欧美人与性动交α欧美软件| 1024香蕉在线观看| 日韩一卡2卡3卡4卡2021年| 成年版毛片免费区| 久久精品人人爽人人爽视色| 欧美大码av| 亚洲专区中文字幕在线| 大型av网站在线播放| 淫妇啪啪啪对白视频| 亚洲精品一区av在线观看| 一级,二级,三级黄色视频| 99精品在免费线老司机午夜| 两个人免费观看高清视频| 亚洲色图 男人天堂 中文字幕| 精品国产国语对白av| 久久精品国产亚洲av香蕉五月| 真人一进一出gif抽搐免费| 一本综合久久免费| 中文字幕人妻丝袜一区二区| 色综合欧美亚洲国产小说| 一区二区三区激情视频| 满18在线观看网站| 麻豆一二三区av精品| 国产xxxxx性猛交| 国产精华一区二区三区| 不卡av一区二区三区| 美女高潮喷水抽搐中文字幕| 久久久国产一区二区| 欧美日韩黄片免| 午夜亚洲福利在线播放| 日日爽夜夜爽网站| 免费av毛片视频| 国产成人av教育| 国产精品一区二区精品视频观看| 99精国产麻豆久久婷婷| 正在播放国产对白刺激| 成人三级黄色视频| av福利片在线| 黄网站色视频无遮挡免费观看| 叶爱在线成人免费视频播放| 一级毛片女人18水好多| 久热这里只有精品99| 99热国产这里只有精品6| 午夜激情av网站| av有码第一页| 人人澡人人妻人| 久久国产乱子伦精品免费另类| 黄片大片在线免费观看| 又黄又爽又免费观看的视频| 亚洲狠狠婷婷综合久久图片| 我的亚洲天堂| 国产蜜桃级精品一区二区三区| 一进一出抽搐动态| 亚洲三区欧美一区| 母亲3免费完整高清在线观看| 一级毛片高清免费大全| 亚洲精品一二三| 女人精品久久久久毛片| 精品电影一区二区在线| 高清毛片免费观看视频网站 | 欧美日韩国产mv在线观看视频| 看片在线看免费视频| 国产不卡一卡二| 欧美色视频一区免费| 美女国产高潮福利片在线看| 欧美激情高清一区二区三区| 久久影院123| 麻豆久久精品国产亚洲av | 两性午夜刺激爽爽歪歪视频在线观看 | 欧美久久黑人一区二区| 又黄又爽又免费观看的视频| 巨乳人妻的诱惑在线观看| 天天添夜夜摸| 美女 人体艺术 gogo| 丝袜美足系列| 国产精品久久久av美女十八| 91av网站免费观看| e午夜精品久久久久久久| 国产熟女xx| 神马国产精品三级电影在线观看 | 这个男人来自地球电影免费观看| 国产精品 欧美亚洲| 在线观看66精品国产| 久热这里只有精品99| 久久这里只有精品19| 亚洲三区欧美一区| 一级,二级,三级黄色视频| 精品久久久精品久久久| 久久精品人人爽人人爽视色| 久久青草综合色| 婷婷六月久久综合丁香| 精品欧美一区二区三区在线| 久久人人精品亚洲av| 国产av又大| 手机成人av网站| 淫秽高清视频在线观看| 亚洲色图综合在线观看| 亚洲男人天堂网一区| 一级片'在线观看视频| 亚洲av成人不卡在线观看播放网| 久9热在线精品视频| 久热爱精品视频在线9| 黄色视频,在线免费观看| 精品国产乱子伦一区二区三区| 两个人免费观看高清视频| 亚洲一区高清亚洲精品| av中文乱码字幕在线| tocl精华| 夜夜看夜夜爽夜夜摸 | 亚洲av成人一区二区三| 亚洲中文av在线| 成人影院久久| 精品人妻在线不人妻| 国产成人欧美在线观看| 日本五十路高清| 久久香蕉激情| 亚洲国产欧美日韩在线播放| 久久性视频一级片| 亚洲精品成人av观看孕妇| 狠狠狠狠99中文字幕| 精品国产一区二区久久| 一区二区三区激情视频| 十八禁人妻一区二区| 亚洲av五月六月丁香网| 日本a在线网址| 久久久久久久久中文| 美女高潮喷水抽搐中文字幕| 久久热在线av| 亚洲,欧美精品.| 熟女少妇亚洲综合色aaa.| 午夜免费成人在线视频| 69精品国产乱码久久久| 超碰97精品在线观看| 一级,二级,三级黄色视频| 久久精品亚洲熟妇少妇任你| 午夜亚洲福利在线播放| 久久精品国产综合久久久| 长腿黑丝高跟| xxxhd国产人妻xxx| 天堂√8在线中文| 久久热在线av| 国产成年人精品一区二区 | 欧美激情极品国产一区二区三区| 亚洲精品久久午夜乱码| 中文字幕人妻丝袜一区二区| 人人妻人人添人人爽欧美一区卜| 国产精品一区二区三区四区久久 | 久久久久国内视频| av免费在线观看网站| 亚洲一码二码三码区别大吗| 欧美性长视频在线观看| 久久精品国产亚洲av高清一级| 黑人操中国人逼视频| 99在线人妻在线中文字幕| 制服人妻中文乱码| 黄片小视频在线播放| 国产片内射在线| 在线观看免费视频网站a站| 性欧美人与动物交配| 韩国av一区二区三区四区| 精品乱码久久久久久99久播| 正在播放国产对白刺激| 国产欧美日韩一区二区三| 欧美丝袜亚洲另类 | 老鸭窝网址在线观看| 亚洲一区高清亚洲精品| 女性被躁到高潮视频| 国产主播在线观看一区二区| 两性夫妻黄色片| 国产成人免费无遮挡视频| 欧美av亚洲av综合av国产av| 久久天躁狠狠躁夜夜2o2o| av天堂久久9| 国产精品综合久久久久久久免费 | 80岁老熟妇乱子伦牲交| 青草久久国产| 亚洲欧美一区二区三区久久| 国产主播在线观看一区二区| 热99re8久久精品国产| 老司机靠b影院| tocl精华| 三上悠亚av全集在线观看| 久9热在线精品视频| 亚洲精品国产区一区二| 别揉我奶头~嗯~啊~动态视频| 动漫黄色视频在线观看| 成人手机av| 中文亚洲av片在线观看爽| www.www免费av| 一级黄色大片毛片| 在线观看免费日韩欧美大片| 欧美亚洲日本最大视频资源| 欧美乱妇无乱码| 在线观看免费视频日本深夜| 久久人妻福利社区极品人妻图片| 天堂影院成人在线观看| 99久久人妻综合| 91国产中文字幕| 欧美性长视频在线观看| 最近最新中文字幕大全免费视频| 777久久人妻少妇嫩草av网站| 久久亚洲真实| 在线观看免费视频日本深夜| 黄片大片在线免费观看| 亚洲国产欧美日韩在线播放| 人人妻人人澡人人看| 欧美一区二区精品小视频在线| 在线观看日韩欧美| 亚洲精品在线观看二区| 少妇的丰满在线观看| 日韩成人在线观看一区二区三区| 精品午夜福利视频在线观看一区| 日韩精品免费视频一区二区三区| 亚洲欧洲精品一区二区精品久久久| 91麻豆精品激情在线观看国产 | 久久久国产精品麻豆| 亚洲中文日韩欧美视频| 大陆偷拍与自拍| 91九色精品人成在线观看| 久久人妻福利社区极品人妻图片| 岛国在线观看网站| 久久久久国内视频| 亚洲精品中文字幕在线视频| 视频区图区小说| 亚洲伊人色综图| 亚洲成a人片在线一区二区| 亚洲成人免费av在线播放| 国产区一区二久久| 男人舔女人下体高潮全视频| 国产高清国产精品国产三级| 亚洲精品美女久久av网站| 91精品国产国语对白视频| 亚洲av日韩精品久久久久久密| 亚洲av成人一区二区三| 日日干狠狠操夜夜爽| 欧美日韩av久久| 日韩高清综合在线| 女人被躁到高潮嗷嗷叫费观| 99久久精品国产亚洲精品| 丁香欧美五月| 色尼玛亚洲综合影院| 国产精品免费一区二区三区在线| 日日夜夜操网爽| 国产成人精品在线电影| 欧美精品啪啪一区二区三区| 又大又爽又粗| 老熟妇仑乱视频hdxx| 久久这里只有精品19| 亚洲自拍偷在线| 高清av免费在线| 丰满的人妻完整版| 夜夜躁狠狠躁天天躁| 19禁男女啪啪无遮挡网站| 99久久99久久久精品蜜桃| 黄频高清免费视频| 一级黄色大片毛片| 午夜精品久久久久久毛片777| 三上悠亚av全集在线观看| 99久久精品国产亚洲精品| 一级a爱片免费观看的视频| 高清av免费在线| 国产野战对白在线观看| 国产成人一区二区三区免费视频网站| 午夜免费成人在线视频| 99久久综合精品五月天人人| 精品人妻在线不人妻| 真人做人爱边吃奶动态| 国产成人精品在线电影| 色婷婷久久久亚洲欧美| 一边摸一边抽搐一进一小说| 999精品在线视频| 国产国语露脸激情在线看| 午夜影院日韩av| 校园春色视频在线观看| 88av欧美| 精品国产国语对白av| 一个人免费在线观看的高清视频| 不卡av一区二区三区| 亚洲五月天丁香| 成人特级黄色片久久久久久久| 亚洲一卡2卡3卡4卡5卡精品中文| 亚洲伊人色综图| 精品日产1卡2卡| 少妇被粗大的猛进出69影院| 亚洲欧美日韩高清在线视频| 露出奶头的视频| 欧美精品啪啪一区二区三区| 男人的好看免费观看在线视频 | 操美女的视频在线观看| 国产精品香港三级国产av潘金莲| 久久热在线av| 国产成人精品在线电影| 一边摸一边抽搐一进一出视频| www.www免费av| 国产精品综合久久久久久久免费 | 丰满人妻熟妇乱又伦精品不卡| 一二三四社区在线视频社区8| 黑人操中国人逼视频| 大型av网站在线播放| 黄网站色视频无遮挡免费观看| 国产欧美日韩综合在线一区二区| 国产精品久久久av美女十八| av天堂久久9| 国产精品日韩av在线免费观看 | 亚洲国产毛片av蜜桃av| 国产精品永久免费网站| 国产午夜精品久久久久久| 日韩免费高清中文字幕av| 亚洲黑人精品在线| 悠悠久久av| 两人在一起打扑克的视频| 久久精品aⅴ一区二区三区四区| 国产成人av激情在线播放| 天天添夜夜摸| 久热爱精品视频在线9| 99精品久久久久人妻精品| 在线视频色国产色| 国产aⅴ精品一区二区三区波| 啦啦啦 在线观看视频| 一本大道久久a久久精品| 亚洲国产欧美一区二区综合| 丝袜在线中文字幕| 老司机午夜福利在线观看视频| 宅男免费午夜| 亚洲欧美一区二区三区久久| 国产精品久久视频播放| 好男人电影高清在线观看| 一级片'在线观看视频| 国产精品二区激情视频| 国产成+人综合+亚洲专区| 18美女黄网站色大片免费观看| ponron亚洲| 自拍欧美九色日韩亚洲蝌蚪91| 午夜免费观看网址| 国产亚洲精品综合一区在线观看 | 亚洲精品国产区一区二| 亚洲成国产人片在线观看| 亚洲视频免费观看视频| 精品国产国语对白av| 最近最新免费中文字幕在线| 欧美一区二区精品小视频在线| 自拍欧美九色日韩亚洲蝌蚪91| 国产精品二区激情视频| 高清欧美精品videossex| 超色免费av| 亚洲精品在线观看二区| 丰满人妻熟妇乱又伦精品不卡| 国产精品日韩av在线免费观看 | 在线观看免费视频网站a站| 欧美最黄视频在线播放免费 | 中文字幕高清在线视频| 亚洲黑人精品在线| 天天躁夜夜躁狠狠躁躁| 国产成人啪精品午夜网站| 国产黄a三级三级三级人| 亚洲va日本ⅴa欧美va伊人久久| 国产色视频综合| 天天躁狠狠躁夜夜躁狠狠躁| 人人澡人人妻人| 国产伦人伦偷精品视频| 一区二区三区激情视频| 欧美中文日本在线观看视频| 美女高潮喷水抽搐中文字幕| 免费在线观看视频国产中文字幕亚洲| 桃红色精品国产亚洲av| 久久国产乱子伦精品免费另类| 9色porny在线观看| 天堂中文最新版在线下载| 亚洲 欧美 日韩 在线 免费| 国产成人欧美在线观看| 一进一出好大好爽视频| 国产在线精品亚洲第一网站| 欧美黑人欧美精品刺激| 一级毛片高清免费大全| 欧美黄色片欧美黄色片| 一级毛片精品| 母亲3免费完整高清在线观看| 亚洲全国av大片| 黑人猛操日本美女一级片| 琪琪午夜伦伦电影理论片6080| 九色亚洲精品在线播放| 亚洲人成伊人成综合网2020| 国产一卡二卡三卡精品| 国产伦一二天堂av在线观看| 成人手机av| 亚洲第一av免费看| 久久青草综合色| 免费搜索国产男女视频| 国产深夜福利视频在线观看| 丰满人妻熟妇乱又伦精品不卡| 嫩草影院精品99| 一区二区三区激情视频| 大码成人一级视频| 女生性感内裤真人,穿戴方法视频| 亚洲色图av天堂| 日本一区二区免费在线视频| 他把我摸到了高潮在线观看| 午夜福利影视在线免费观看| 欧美日韩视频精品一区| 欧美在线黄色| 一级毛片高清免费大全| 十八禁人妻一区二区| 成人三级黄色视频| 日日爽夜夜爽网站| 亚洲一区二区三区欧美精品| 村上凉子中文字幕在线| 欧美最黄视频在线播放免费 | 国产成+人综合+亚洲专区| 男人操女人黄网站| 久久亚洲精品不卡| 国产成人免费无遮挡视频| 一边摸一边抽搐一进一小说| 亚洲美女黄片视频| 脱女人内裤的视频| 免费人成视频x8x8入口观看| 99国产极品粉嫩在线观看| 黄片播放在线免费| 国产成人精品无人区| 亚洲av成人不卡在线观看播放网| 丰满迷人的少妇在线观看| 亚洲国产精品一区二区三区在线| 纯流量卡能插随身wifi吗| 黄色丝袜av网址大全| 黄频高清免费视频| 亚洲专区中文字幕在线| 久久影院123| 在线看a的网站| 亚洲av成人不卡在线观看播放网| 欧美久久黑人一区二区| 交换朋友夫妻互换小说|